Cost effectiveness of female HPV vaccines for routine childhood immunisation schedule in Turkiye.

ABSTRACT:

Objective

To evaluate the cost-effectiveness of introducing Human Papillomavirus (HPV) vaccination into Türkiye's National Immunization Program.

Methods

The analysis employed the WHO-endorsed PRIME model in Microsoft Excel. Two vaccination strategies were simulated for 12-year-old girls: Scenario 1 (bivalent or quadrivalent vaccine) and Scenario 2 (nonavalent vaccine). Each scenario was assessed from both the Social Security Institution (SGK) and societal perspectives. Incremental cost-effectiveness ratios (ICERs) were calculated per disability-adjusted life year (DALY) averted, with sensitivity analyses conducted to test model robustness.

Results

Scenario 1 yielded an ICER of USD 2,231 per DALY averted, while Scenario 2 produced an ICER of USD 2,342. The incremental

SUBMITTER: Sahin CE 

PROVIDER: S-EPMC12542382 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature